Biotech Values

[DewDiligence]

The ‘486 patent licensed from Ludwig last November appears to be limited to the use of IL-9-based conjugates in therapeutic vaccines:

http://www.genaera.com/pressreleases/2003_nov13.html

>>
Plymouth Meeting, PA, November 13, 2003 /PRNewswire/ - Genaera Corporation (NASDAQ: GENR) today announced issuance by the United States Patent and Trademark Office of patent number 6,645,486 covering claims for reducing the activity of interleukin-9 comprising administering a conjugate of IL-9 and a carrier sufficient to induce production of IL-9 specific antibodies which bind to and reduce IL-9 activity. The patent is entitled “Method of Treatment with IL-9 Conjugate.” The patent assigned to the Ludwig Institute of Cancer Research is subject to a license granted to Genaera.
“Treatment of asthma and other IL-9 related conditions using a vaccine technology to generate specific antibodies may be an attractive future treatment option,” noted Roy C. Levitt, M.D. President and Chief Executive Officer. "We look forward to pursuing program specific funding to continue this promising preclinical research” [emphasis added].
<<